Pegbio, a Suzhou-based biopharmaceutical company that specialises in innovative drugs for diabetes and obesity, announced on Tuesday that it has secured around 800 million yuan ($122 million) in a pre-IPO round co-led by Jack Ma’s YF Capital, private equity firm Yingke PE, and life sciences-focussed investment firm TF Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
